Why the study?
Does anticoagulation with DOACs or warfarin reduce ischemic stroke or systemic embolism in patients with end-stage kidney disease and atrial fibrillation on hemodialysis?
Does anticoagulation with DOACs or warfarin reduce ischemic stroke or systemic embolism in patients with end-stage kidney disease and atrial fibrillation on hemodialysis?
Answers are grounded in this paper and cite their sources.
In hemodialysis patients with atrial fibrillation, DOACs offer a more favorable risk-benefit ratio than warfarin for stroke prevention, though both significantly increase bleeding risk compared to no anticoagulation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Tae-Wan Chung (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: